Loading...
Market
Will Zevra Therapeutics announce a new clinical trial for Miplyffa by Mar 31, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Press releases from Zevra Therapeutics or clinical trial registries like ClinicalTrials.gov
Story
FDA Approves Zevra's Miplyffa for Niemann-Pick Disease Type C
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved the first oral medication to treat Niemann-Pick disease, type C (NPC). The drug, developed by Zevra Therapeutics and named Miplyffa (arimoclomol), is approved in combination with miglustat for patients aged 2 and older. This marks the first treatment to receive approval for this rare and fatal genetic disorder. The approval was announced on Friday. Zevra Therapeutics is listed under the ticker symbol ZVRA.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Yes • 50%
No • 50%
